The aim of this study was to develop a formulation containing fenofibrate and Gelucire® 50/13 (Gattefossé, France) in order to improve the oral bioavailability of
the drug. Particles from Gas Saturated Solutions (PGSS) process was chosen for investigation as a manufacturing process for producing a solid dispersion
http://www.ncbi.nlm.nih.gov/pubmed/25796121
Int J Pharm. 2015 Mar 18. pii: S0378-5173(15)00243-4. doi: 10.1016/j.ijpharm.2015.03.027. [Epub ahead of print]